Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

A Phase IIa, Placebo Controlled, Multicenter Pilot Study to Evaluate the Safety and Efficacy of BIO-11006 Inhalation Solution in Patients With Acute Respiratory Distress Syndrome

This Phase IIa pilot study is a placebo controlled, multicenter study to evaluate safety and efficacy of aerosolized BIO-11006 Inhalation Solution in ARDS patients. The subjects will be randomized 1:1 to either BIO-11006 125 mg twice daily plus standard of care or placebo plus standard of care. The treatment will continue for up to 28 days. The study will enroll up to 40 adult ARDS patients in up to eight sites within USA.

Study Overview

• Status: Completed
• Conditions: Respiratory Distress Syndrome, Adult
• Intervention / Treatment: Drug: BIO-11006; Drug: Placebo

Detailed Description

This is a randomized, double blind, placebo controlled, parallel-group Phase IIa pilot study of aerosolized BIO 11006 in patients with sepsis-induced acute respiratory distress syndrome (ARDS). All patients enrolled in the study will be ventilated. To be eligible for enrollment, patients must be adults who have sepsis-induced ARDS within 48 hours prior to enrollment, require intubation, and exhibit bilateral infiltrates consistent with pulmonary edema on the frontal chest radiograph within 48 hours of enrollment. Patients will be randomized in a 1:1 ratio to either BIO-11006 125 mg twice daily (BID) plus standard of care ventilation or placebo (half normal saline [HNS]) BID plus standard of care ventilation. Patients randomized to receive BIO-11006 or placebo will start dosing at the time of ventilation and continue for up to 28 days or length of ventilation (if shorter). Patients in both groups will receive best available standard of care treatment, including low-volume mechanical ventilation as indicated by clinical judgment and patient response. The maximum duration of treatment will be 30 days.

The primary objective of this study is to evaluate the safety and efficacy of aerosolized BIO-11006 at a dose of 125 mg BID in ventilated patients who have ARDS. Safety is the primary endpoint in this study and will be monitored by adverse event reporting, oxygenation, mortality, vital signs, ventilator-free days, and ICU-free days.

This study will enroll up to 40 adult patients with ARDS induced by sepsis who first met the Berlin Criteria for ARDS within 48 hours of enrollment, and who require intubation and exhibit bilateral opacities consistent with pulmonary edema on frontal chest radiograph within 48 hours of enrollment.

BIO 11006 Inhalation Solution drug product is formulated at a dosage strength of 41.67 mg/mL (125 mg/3 mL) as an aqueous solution containing sodium chloride and is intended for aerosol administration by the "Aeroneb Pro®" nebulizer to patients randomized to active treatment.

• Study Type: Interventional
• Enrollment (Actual): 38
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60637
      • University of Chicago Medicine
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • University of North Carolina School of Medicine
    • Winston-Salem, North Carolina, United States, 27157
      • Wake Forest University
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • University of Pennsylvania
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Vanderbilt University, Div of Allergy, Pulmonary, Critical Care

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Has provided (or relative has) written informed consent and authorization for use and disclosure of protected health information

2. Has a clinical diagnosis of sepsis or septic shock defined as:

   • Known or suspected infection

   • Systemic inflammatory response syndrome (SIRS), defined as meeting at least 2 of the following 3 criteria for a systemic inflammatory response:

     • White blood cell count >12,000 or <4,000 or >10% band forms
     • Body temperature >38°C (any route) or <36°C (by core temperatures only: indwelling catheter, esophageal, rectal)
     • Heart rate >90 beats/min or receiving medications that slow heart rate or pace rhythm

3. Enrollment must occur within 48 hours of first meeting ARDS criteria per the Berlin definition of ARDS (ARDS Task Force 2012) and no more than 72 hours from the initiation of mechanical ventilation. (The bilateral opacities, respiratory failure, and decreased P/F ratio must all be present within a 24 hour time period of one another.):

   • Lung injury of acute onset, within 1 week of an apparent clinical insult, with progression of respiratory symptoms
   • Bilateral opacities on chest imaging not fully explained by effusions, lobar/lung collapse, or nodules.
   • Respiratory failure not fully explained by cardiac failure or fluid overload. (Need objective assessment (e.g. echocardiography) to exclude hydrostatic edema if no risk factor present.)

   • Decreased arterial partial pressure of oxygen (PaO2)/ fraction of inspired oxygen (FIO2) ratio while on a minimum Positive End Expiratory Pressure (PEEP) of 5 cm water (H2O):

     • Moderate ARDS: 101 to 200 mmHg (≤ 26.6 kPa)
     • Severe ARDS: ≤ 100 mmHg (≤ 13.3 kPa)

Exclusion Criteria:

1. Age < 18 years or >75 years old
2. Greater than 48 hours since first meeting ARDS criteria per the Berlin definition of ARDS
3. Pregnant or breastfeeding (negative pregnancy test required prior to randomization for female patients of childbearing potential.)
4. Prisoner
5. Any other irreversible disease or condition for which 6 month mortality is estimated to be > 50%
6. Moderate to severe liver failure (Child Pugh Score > 12)
7. Severe chronic respiratory disease with a PaCO2 > 50 mmHg or the use of home oxygen
8. Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest).
9. Major trauma in the prior 5 days
10. Lung transplant patient
11. No consent/inability to obtain consent
12. Moribund patient not expected to survive 24 hours
13. World Health Organization (WHO) Functional Class III or IV pulmonary hypertension
14. No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol
15. Currently receiving extracorporeal life support or high frequency oscillatory ventilation
16. Known hypersensitivity to BIO 11006
17. Burn victims >20% Total Body Surface Area (TBSA) or with known airway inhalation injury

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Active intervention; Patients will be randomized in a 1:1 ratio to either aerosolized BIO-11006 (125mg in 3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or placebo.	Drug: BIO-11006; Intervention involves aerosolized delivery of either the active drug or placebo by the "Aeroneb Pro nebulizer".
PLACEBO_COMPARATOR: Placebo intervention; Patients will be randomized in a 1:1 ratio to either aerosolized placebo (3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or active drug.	Drug: Placebo; Intervention involves aerosolized delivery of either the active drug or placebo by the "Aeroneb Pro nebulizer".; Other Names: Half Normal saline

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of treatment-emergent adverse events	Assessment of frequency, type, severity, and duration of treatment-emergent Adverse Events (AE) daily during 28 day treatment period, including clinically significant laboratory abnormalities	28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of mortality	Mortality will be assessed daily during treatment for 28 days and at day 180 after enrollment.	End of treatment period (28 days) and end of follow up period (180 days)
Number of Intensive Care Unit (ICU)-free days	Number of days not in the ICU assessed daily during the 28 day treatment period.	28 days
Number of ventilator-free days	Number of days off the ventilator assessed daily during 28 day treatment	28 days
Change in oxygen saturation / fraction of inspired oxygen (S/F) ratio	Change in theS/F ratio assessed daily during the 28 day treatment period	28 days
Change in pro-inflammatory biomarkers from baseline to end of treatment	ARDS associated biomarkers will be measured in plasma	pretreatment and end of treatment period (28 days)

Collaborators and Investigators

• Sponsor: BioMarck Pharmaceuticals, Ltd.
• Investigators: Study Chair: Brian Dickson, MD, Biomarck Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 5, 2017
• Primary Completion (ACTUAL): March 30, 2020
• Study Completion (ACTUAL): June 15, 2020

Study Registration Dates

• First Submitted: June 20, 2017
• First Submitted That Met QC Criteria: June 27, 2017
• First Posted (ACTUAL): June 28, 2017

Study Record Updates

• Last Update Posted (ACTUAL): June 25, 2020
• Last Update Submitted That Met QC Criteria: June 23, 2020
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Keywords: edema; sepsis; intubation; aerosol
• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Respiration Disorders; Lung Diseases; Disease; Infant, Newborn, Diseases; Lung Injury; Infant, Premature, Diseases; Syndrome; Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Acute Lung Injury
• Other Study ID Numbers: BIM-CL-005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No